United States Parkinson's Disease Therapeutics Market valuation $12.83 billion by 2033 - Exclusive Report by DatamIntelligence

"The global Parkinson's disease therapeutics market size reached US$ 5.92 Billion in 2024 and is expected to reach US$ 12.83 Billion by 2033, growing at a CAGR of 8.1% during the forecast period 2025-2033." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/parkinsons-disease-therapeutics-market?sp

United States: Recent Industry Developments

✅ In September 2025, Biogen launched a Phase 3 trial for a novel gene therapy targeting Parkinson's disease to slow neurodegeneration. The therapy aims to restore dopamine production in affected neurons. It strengthens U.S. efforts in advanced neurotherapeutics.

✅ In August 2025, AbbVie invested $200 million in expanding its Parkinson's research program, focusing on disease-modifying small molecules and biologics. The investment accelerates the development of innovative therapies. It enhances the U.S. Parkinson's disease treatment pipeline.

✅ In July 2025, Voyager Therapeutics announced a collaboration with a biotech startup to develop viral vector-based therapies for Parkinson's. The program focuses on targeted gene delivery to affected brain regions. It supports U.S. innovation in neurodegenerative disease treatment.

✅ In June 2025, the Michael J. Fox Foundation funded a multicenter study evaluating stem cell-derived neuron transplants in Parkinson's patients. The study aims to restore motor function and reduce disease progression. It advances clinical research in the U.S. Parkinson's ecosystem.

Japan: Recent Industry Developments

✅ In September 2025, Eisai Co., Ltd. initiated a Phase 2 trial for a novel small-molecule therapy aimed at slowing Parkinson's disease progression. The therapy targets alpha-synuclein aggregation in neurons. It strengthens Japan's neurodegenerative disease research.

✅ In August 2025, Takeda Pharmaceutical invested in AI-driven discovery of Parkinson's therapeutics, focusing on early-stage biomarkers and precision-targeted treatments. The initiative enhances Japan's drug development capabilities.

✅ In July 2025, Mitsubishi Tanabe Pharma launched a clinical study testing an innovative dopamine agonist formulation to improve motor function in Parkinson's patients. The study emphasizes patient compliance and symptom control. It supports Japan's advanced therapeutics development.

✅ In June 2025, Kyoto University Hospital initiated a pilot program evaluating stem cell-derived therapies for Parkinson's disease. The program aims to restore neuronal function and delay disease progression. It contributes to Japan's regenerative medicine initiatives.

Parkinson's disease Therapeutics Market: Drivers

The Parkinson's disease therapeutics market is witnessing growth due to the increasing prevalence of Parkinson's disease, driven by aging populations and rising awareness of neurodegenerative disorders worldwide. Treatments, including dopaminergic therapies, MAO-B inhibitors, COMT inhibitors, and emerging gene and cell-based therapies, aim to manage motor and non-motor symptoms, slow disease progression, and improve patient quality of life. Technological advancements in precision medicine, novel drug delivery systems, and neuroprotective therapies are enhancing efficacy, safety, and patient compliance. Rising investments from pharmaceutical companies, research institutions, and government initiatives are accelerating development of innovative therapeutics. Additionally, growing emphasis on early diagnosis, continuous monitoring, and personalized care is further supporting market adoption.

Innovations in deep brain stimulation adjuncts, immunotherapies, and disease-modifying approaches are providing new avenues for managing Parkinson's disease and associated complications. Integration with digital health tools, wearable monitoring devices, and AI-driven treatment planning is improving patient adherence, symptom tracking, and clinical decision-making. Increasing awareness of the social and economic burden of Parkinson's disease is driving demand for advanced, effective, and accessible therapies. Collaborations between biotech firms, academic institutions, and healthcare providers are accelerating clinical trials, research, and commercialization of next-generation therapeutics. Collectively, these factors are driving sustained growth in the Parkinson's disease therapeutics market as stakeholders prioritize innovative, personalized, and effective treatment strategies for neurodegenerative disorders.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/parkinsons-disease-therapeutics-market?sp

Parkinson's disease Therapeutics Market: Major Players

F. Hoffmann-La Roche Ltd, AbbVie Inc., Supernus Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Merck & Co., Inc., Boehringer Ingelheim International GmbH, GSK plc, Novartis AG, UCB S.A., Kyowa Kirin Co., Ltd., Merz Pharmaceuticals, LLC, and Bausch He

Segment Covered in the Parkinson's disease Therapeutics Market:

➥ By Type: Idiopathic Parkinson's Disease, Familial Parkinson's Disease, Early-onset Parkinson's Disease

➥ By Drug Class: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, Amantadine & Derivatives, Adenosine A2A Receptor Antagonists, Others

➥ By Route of Administration: Oral, Injectable, Transdermal

➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Research Process:

Both primary and secondary data sources have been used in the Parkinson's disease Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Parkinson's disease Therapeutics Market Research Industry:

➠ Who leads the Parkinson's disease Therapeutics industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Parkinson's disease Therapeutics market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Parkinson's disease Therapeutics market growth?
➠ What are the dominant sales and distribution strategies in the Parkinson's disease Therapeutics industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=parkinsons-disease-therapeutics-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.